Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019997 | 0.79 | NR1I2 (0.46) | ALDH1A1 | |
| SCHEMBL5426437 | 0.79 | NLRP3 (0.39) | NLRP3LMNAPOLBALDH1A1 | |
| SCHEMBL30765414 | 0.77 | NLRP3 (0.50) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL21662426 | 0.74 | NLRP3 (0.40) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL12125349 | 0.74 | NLRP3 (0.40) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL29045575 | 0.74 | LMNA (0.62) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL873613 | 0.73 | LMNA (0.76) | LMNAPOLBALDH1A1 | |
| SCHEMBL12224209 | 0.73 | NLRP3 (0.39) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL12662616 | 0.73 | NLRP3 (0.45) | NLRP3LMNAPOLBALDH1A1LPAR1 | |
| SCHEMBL1842777 | 0.73 | NLRP3 (0.45) | NLRP3LMNAPOLBALDH1A1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1180104-A1 | METHODS OF SEPARATING FTC ISOMERS AND DERIVATIVES THEREOF | Pharm-Eco Laboratories Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000071539-A1 | METHODS OF SEPARATING FTC ISOMERS AND DERIVATIVES THEREOF | PHARM-ECO LABORATORIES INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20110257396-A1 | PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE | LUPIN LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
| EP-1180104-A1 | METHODS OF SEPARATING FTC ISOMERS AND DERIVATIVES THEREOF | Pharm-Eco Laboratories Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000071539-A1 | METHODS OF SEPARATING FTC ISOMERS AND DERIVATIVES THEREOF | PHARM-ECO LABORATORIES INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257396-A1 | PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE | TYMS, TYMP, SAMHD1 | NLRP3 3472/4885LMNA 643/4885POLB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.